TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its price target raised by analysts at HC Wainwright from $3.00 to $20.00. They now have a "buy" rating on the stock.
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial [Yahoo! Finance]
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TransCode Therapeutics, Inc. Announces $8 Million Private Placement [Yahoo! Finance]